
Neuronetics Inc (STIM) Stock Forecast & Price Target
Neuronetics Inc (STIM) Analyst Ratings
Bulls say
Neuronetics Inc. has demonstrated a notable sequential increase in capital sales, reaching $4.4 million, reflecting a strong upward trajectory in its business performance. The company has reported an 18% year-over-year increase in its local consumables segment, further supporting the operational growth and indicating robust demand for its NeuroStar Advanced Therapy System. Additionally, with improvements observed in Greenbrook sites and enhanced efficiency metrics for participating practices, Neuronetics is positioned for increased revenue growth and an accelerated path to profitability amid a strengthening balance sheet, indicating a positive outlook for its financial future.
Bears say
Neuronetics, Inc. has reported a significant decline in revenue, with NeuroStar revenues falling to $4.0 million, reflecting an 11% year-over-year decrease. The company's sales guidance for Q3 2024, projected between $18.5 million to $19.5 million, is below analysts' expectations, indicating a 6% decrease compared to prior guidance. Additionally, the impact of a cybersecurity incident has contributed to revenue shortfalls, with management citing a cash collection shortage of approximately $2 million, compounding the challenges faced by the company.
This aggregate rating is based on analysts' research of Neuronetics Inc and is not a guaranteed prediction by Public.com or investment advice.
Neuronetics Inc (STIM) Analyst Forecast & Price Prediction
Start investing in Neuronetics Inc (STIM)
Order type
Buy in
Order amount
Est. shares
0 shares